Qualification of M30 and M65 ELISAs as surrogate biomarkers of cell death: long term antigen stability in cancer patient plasma
Affiliation
Clinical and Experimental Pharmacology Group, Paterson Institute for Cancer Research, University of Manchester, Wilmslow Road, Manchester, M20 4BX, England. jcummings@picr.man.ac.ukIssue Date
2007-11
Metadata
Show full item recordAbstract
PURPOSE: M30 and M65 ELISAs are proposed as surrogate biomarkers of tumour cell death in patients and are being applied increasingly in the pharmacodynamic (PD) evaluation of anticancer drugs during clinical trials. In the absence of such data, we have studied the long-term stability of the antigens of both assays in plasma of cancer patients stored at -80 degrees C over 2 years. RESULTS: No evidence was detected of degradation in the M65 antigen. However, in a proportion of patients significant increases in levels of M30 antigen were detected CONCLUSION: Plasma samples for M65 analysis can be stored at -80 degrees C for 2 years; however, caution is recommended when considering long-term storage of samples for the M30 assay.Citation
Qualification of M30 and M65 ELISAs as surrogate biomarkers of cell death: long term antigen stability in cancer patient plasma. 2007, 60 (6):921-4 Cancer Chemother. Pharmacol.Journal
Cancer Chemotherapy and PharmacologyDOI
10.1007/s00280-007-0437-4PubMed ID
17333190Type
ArticleLanguage
enISSN
0344-5704ae974a485f413a2113503eed53cd6c53
10.1007/s00280-007-0437-4
Scopus Count
Collections
Related articles
- Utilization of cytokeratin-based biomarkers for pharmacodynamic studies.
- Authors: Linder S, Olofsson MH, Herrmann R, Ulukaya E
- Issue date: 2010 Apr
- Elevated serum levels of M30 and M65 in patients with locally advanced head and neck tumors.
- Authors: Ozturk B, Coskun U, Sancak B, Yaman E, Buyukberber S, Benekli M
- Issue date: 2009 May
- Is there any impact of plasma M30 and M65 levels on progression-free survival of patients with advanced gastric cancer?
- Authors: Bilici A, Ustaalioglu BB, Ercan S, Orcun A, Seker M, Salepci T, Gumus M
- Issue date: 2011 Aug
- Application of the β-expectation tolerance interval to method validation of the M30 and M65 ELISA cell death biomarker assays.
- Authors: Cummings J, Zhou C, Dive C
- Issue date: 2011 Apr 15
- Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer.
- Authors: de Haas EC, di Pietro A, Simpson KL, Meijer C, Suurmeijer AJ, Lancashire LJ, Cummings J, de Jong S, de Vries EG, Dive C, Gietema JA
- Issue date: 2008 Oct